首页> 外国专利> Oral administration of Caoxi pasteurized suspension

Oral administration of Caoxi pasteurized suspension

机译:口服西药巴氏灭菌悬浮液

摘要

It refers to the oral suspension composition of oxacarbazepina (10.11-dihydro-10-oxo-5h-di-benz [b, F] azepin-5-carboxamida), from 1% g / ml to 20% g / ml; the mixture of microcrystalline cellulose, from 1.25% g / ml to 1.95% g / ml; antioxidant, such as acorbico (0.75% g / ml, 2 g / ml); Its physical and chemical properties are as follows: pH value is 2-4; when vibrating, its viscosity is 5 MPa / s to 52 MPA / s. its composition is oral sulfur phosphorus suspension, which can freely leak out from an orifice with 3 mm diamond,At the speed of 0.3ml/s to 4ml / s, synthesis can be used to treat a wide range of main acoustic clone attacks and local attacks.
机译:它是指草酸卡巴西平(10.11-dihydro-10-oxo-5h-di-benz [b,F] azepin-5-carboxamida)的口服混悬液组合物,含量为1%g / ml至20%g / ml;微晶纤维素的混合物,从1.25%g / ml至1.95%g / ml;抗氧化剂,例如抗坏血酸(0.75%g / ml,2 g / ml);其理化性质如下:pH值为2-4; pH值为2。振动时,其粘度为5 MPa / s至52 MPA / s。它的成分是口服硫磷悬浮液,可以通过3 mm金刚石从孔中自由泄漏,以0.3ml / s至4ml / s的速度合成可用于治疗各种主要的声学克隆攻击和局部攻击。

著录项

  • 公开/公告号PE20010933A1

    专利类型

  • 公开/公告日2001-09-17

    原文格式PDF

  • 申请/专利权人 NOVARTIS AG;

    申请/专利号PE20000001359

  • 发明设计人 SIGG JUERGEN;BILLINGTON MICHAEL;

    申请日2000-12-18

  • 分类号A61K9/10;A61K31/55;A61P25/12;

  • 国家 PE

  • 入库时间 2022-08-22 01:24:11

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号